Transcript Document

Anti-PD-1/PD-L1 Pipeline Comparison
Compound
Hits *
Development
Status/
Approved
indications
Approved/
mMelanoma (2nd
line, USA)
Approved/
Unresectable
melanoma (JP)
Indications in development
Combination partners
RCC, NSCLC, H&N, BC, MM
+Cytotoxics
+ipilimumab
Squamous cell NSCLC(3rd line,
EU registration)
Non-sq NSCLC, mRCC, CML,
mCRC, GBM, H&N, NHL, HL,
MM, DLBCL
+Cytotoxics
+ipilimumab (Anti-CTLA4)
+bevacizumab
+cetuximab
+urelumab (Anti-CD137)
+Anti-LAG-3 mAb (Anti-LAG-3)
+Anti-KIR mAb (Anti-KIR)
+ipilimumab (anti-CTLA4)
+vemurafinib
+Avastin
+Tarceva
+obinutuzumab
+cobimetinib
+anti-PD-1 mAb (MEDI0680)
+tremelimumab(Anti-CTLA4)
+EGFR Tki
etc
MSD/Keytru
da
(anti-PD-1)
BMS/Ono/
Opdivo
(anti-PD-1)
23
Roche/
RG7446
(MPDL3280)
(anti-PD-L1)
13
P3
Melanoma, RCC, NSCLC, BC
AstraZeneca/
MEDI4736
(anti-PD-L1)
17
P3
Melanoma, mNSCLC, H&N,
CRC,
46
*Search results from clinicaltrials.gov
RCC(renal cell carcinoma), NSCLC(non-small cell lung cancer, H&N(head &neck), BC(bladder cancer), MM (multiple myeloma), CML(chronic
myeloid leukemia), GBM(Glioblastoma Multiforme), NHL (non-Hodgkin lymphoma), HL (Hodgkin lymphoma), DLBCL(diffuse large B cell
lymphoma)